Dr. Shixing Tang received his bachelor's degree in medicine in 1986 and master's degree in public health in 1989 from the Southern Medical University (former First Military Medical University) in Guangzhou, China, as well as his PhD in public health in 1993 from the Academy of Military Medical Sciences in Beijing, China. Dr. Tang was trained as a post-doctoral fellow from 1993 to 1995 in the School of Medicine within Perkin University, and then in the University of Glasgow from 1996 to 1997. He used to work as a visiting fellow and then a staff scientist from 1997 to 2003 in the National Institutes of Health (NIH) in Besthesda, MD, USA. He also worked as a staff scientist in the Food and Drug Administration (FDA) of the USA from 2003 to 2011. During 2011 and 2014, he was recruited as Chief Medical Officer and Chief Technology Officer in a biological company in Guangzhou, China. In 2014, he joined the School of Public Health, Southern Medical Uuniversity and was appointed as a full professor. Currently, Dr. Tang is a principle investigator of Whenzhou Institute within the University of Chinese Academy of Sciences.
Dr. Tang focuses his study on the development of novel in vitro diagnosis and cell-based immunotherapy, in particular for infectious diseases and cancers. He has published more than 70 peer-reviewed papers in Lancet, Annals of Internal Medicine, Clinical Infectious Diseases, Journal of Virology, etc.
Dr. Shixing Tang received his bachelor's degree in medicine in 1986 and master's degree in public health in 1989 from the Southern Medical University (former First Military Medical University) in Guangzhou, China, as well as his PhD in public health in 1993 from the Academy of Military Medical Sciences in Beijing, China. Dr. Tang was trained as a post-doctoral fellow from 1993 to 1995 in the School of Medicine within Perkin University, and then in the University of Glasgow from 1996 to 1997. He used to work as a visiting fellow and then a staff scientist from 1997 to 2003 in the National Institutes of Health (NIH) in Besthesda, MD, USA. He also worked as a staff scientist in the Food and Drug Administration (FDA) of the USA from 2003 to 2011. During 2011 and 2014, he was recruited as Chief Medical Officer and Chief Technology Officer in a biological company in Guangzhou, China. In 2014, he joined the School of Public Health, Southern Medical Uuniversity and was appointed as a full professor. Currently, Dr. Tang is a principle investigator of Whenzhou Institute within the University of Chinese Academy of Sciences.
Dr. Tang focuses his study on the development of novel in vitro diagnosis and cell-based immunotherapy, in particular for infectious diseases and cancers. He has published more than 70 peer-reviewed papers in Lancet, Annals of Internal Medicine, Clinical Infectious Diseases, Journal of Virology, etc.